RESEARCH USE ONLY: All products are for laboratory research purposes only. Not for human or animal consumption.
By using this site, you confirm you are 21+ and acknowledge these products are not FDA approved.
← Back to Research Library
Mechanism of Action
Cagrilintide is a long-acting amylin receptor agonist with fatty acid acylation for once-weekly dosing. It activates area postrema neurons for central appetite suppression, delays gastric emptying, and suppresses post-prandial glucagon. Mechanism is distinct from and complementary to GLP-1 activation.
Key Research Findings
- CagriSema achieved 15.6% weight loss at 32 weeks in Phase 2, exceeding either component alone
- Monotherapy produced dose-dependent weight loss up to 10.8% at 26 weeks
Peer-Reviewed Studies (2)
Enebo LB, Berthelsen KK, et al.
Lancet (2021)
CagriSema combination produced superior weight loss vs either component alone
Lau DCW, Erichsen L, et al.
Lancet (2021)
Cagrilintide produced dose-dependent weight loss up to 10.8% at 26 weeks
Research Disclaimer: The studies referenced above are from publicly available peer-reviewed literature. Pepta Labs products are sold strictly for research purposes. They are not intended for human consumption, therapeutic use, or as dietary supplements. All information is provided for educational and research reference only.